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Abstract
Objective: Paraneoplastic neurological syndromes (PNS) are rare neurological
disorders in which ectopic expression of neural antigens by a tumor results in
an autoimmune attack against the nervous system. Onconeural antibodies not
only guide PNS diagnosis but may also help detecting underlying malignancies.
Our project aims to uncover new potential antibodies in paraneoplastic neu-
ropathies (PN). Methods: Thirty-four patients fulfilling diagnostic criteria of
possible (n = 9; 26.5%) and definite (n = 25; 73.5%) PN without onconeural
antibodies and 28 healthy controls were included in our study. Sera were tested
for known antibodies against neural cell adhesion molecules and screened for
novel IgG and IgM reactivities against nerve components: dorsal root ganglia
(DRG) neurons, motor neurons, and Schwann cells. Patients showing autoanti-
bodies against any of these cell types were used for immunoprecipitation (IP)
studies. Results: Overall, 9 (26.5%) patients showed significant reactivity against
DRG neurons, motor neurons, or Schwann cells, whereas 5 (17.9%) healthy
controls only showed moderate reactivity. Compared with control sera, serum
samples from patients with paraneoplastic sensory-motor neuropathies had a
higher frequency of IgM antibodies against Schwann cells (0% vs. 40%;
P = 0.0028). No novel antigens were identified from our IP experiments. Anti-
bodies against the neural adhesion molecules CNTN1, NF155, NF140, NF186,
NCAM1, L1CAM, and the CNTN1/CASPR1 complex were not detected in
patients with PN. One (2.9%) patient with CIDP and thymoma had CASPR2
antibodies. Interpretation: Almost 30% of patients with PN harbor antibodies
targeting neural structures, suggesting that novel neoplasm-associated antigens
remain to be discovered.
Introduction
Paraneoplastic neurological syndromes (PNS) are
heterogeneous and rare neurological disorders in which
the ectopic expression of a neural antigen in a neo-
plasm drives an autoimmune response resulting in neu-
rological impairment.1 PNS comprise multiple clinical
entities that may affect all parts of the nervous system.1
According to the PNS Euronetwork database, one third
of patients with PNS have the peripheral nervous sys-
tem as the primary site of involvement. Among
peripheral PNS, sensory neuronopathy is the most fre-
quent syndrome.2
In PNS, breakage of tolerance against self follows ecto-
pic expression of tumor-expressed antigens, which leads
to the production of paraneoplastic or onconeural anti-
bodies.1 To date, several well-characterized onconeural
antibodies have been described,3 being anti-Hu and anti-
Yo antibodies the most frequent.2 Except for anti-Hu
antibodies, which strongly associate with pure sensory
neuronopathy, most of these onconeural antibodies asso-
ciate with central nervous system disorders. Since
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neurological symptoms generally precede tumor detec-
tion,4 the finding of circulating onconeural antibodies
may be key in guiding what is often a challenging diagno-
sis.3 Furthermore, their detection in patients is in some
cases invaluable in the discovery of an underlying malig-
nancy, allowing the initiation of an early oncological
treatment which might, in turn, contribute to the man-
agement of the PNS.5–8
Contactin 1 (CNTN1) is an axonal cell adhesion mole-
cule implicated in myelin loops fixation at the paranode
of Ranvier.9 Our group described the presence of anti-
CNTN1 antibodies in small subsets of chronic inflamma-
tory demyelinating polyneuropathy (CIDP) patients with
characteristic clinical features.10 Both in vitro and passive-
transfer experiments in animal models have demonstrated
anti-CNTN1 antibodies’ pathogenicity in CIDP.11 CNTN1
has also been postulated to play a pivotal role in the
development, progression, and pathogenesis of multiple
tumors, being its expression considered as a marker of
poor prognosis.12–16 Two of our CIDP patients harboring
antibodies against CNTN1, respectively, developed a lym-
phoma and a colon adenocarcinoma in addition to their
neuropathy, one of them concomitantly, and the other
several years later. The role of other cell adhesion mole-
cules such as neural cell adhesion molecule 1
(NCAM1)17–20 and L1 (L1CAM)21–23 in cancer pathogen-
esis has been widely described. However, their possible
involvement as antigens in paraneoplastic neuropathies
has not been studied.
Here, we present a prospective study in which sera
from a group of 34 patients fulfilling diagnostic criteria of
possible (n = 9; 26.5%) and definite (n = 25; 73.5%)
paraneoplastic neuropathies (PN), according to the PNS
Euronetwork criteria,3 were analyzed to uncover new
potential antibodies. Sera were tested for known antibod-
ies against neural cell adhesion molecules and screened
for novel reactivities against nerve components.
Materials and Methods
Patients, informed consent, and protocol
approvals
In this prospective study, 34 patients followed at the Neu-
roimmunology-Multiple Sclerosis Unit in Hospital Clınic
de Barcelona (n = 32; 94.1%) or at the Neuromuscular
Diseases Unit in Hospital de Sant Pau (n = 2; 5.9%) were
included. Patients fulfilled diagnostic criteria of possible
(n = 9; 26.5%) or definite (n = 25; 73.5%) PN.3 Periph-
eral nerve involvement due to neoplastic infiltration,
infectious or metabolic complications, or from any sort
of cancer treatment was appropriately ruled out. All
patients lacked antibodies against well-characterized
antigens as determined by immunoblot at Hospital Clınic.
Twenty-eight healthy controls from the Neuromuscular
Diseases Laboratory biobank were additionally included.
Serum samples were obtained and frozen at 80° until
needed.
This clinical research was conducted in compliance
with the Declaration of Helsinki and was approved by the
Human Ethics Committees Review Board of Hospital de
la Santa Creu i Sant Pau and Hospital Clınic de Barce-
lona. Written informed consents were obtained from all
participants.
With regard to experiments involving rats, experimen-
tal procedures were approved by our institution’s Service
of Animal Experimentation at CSIC-ICCC (Institut Catala
de Ciencies Cardiovasculars).
Protocol overview
Sera were tested for antibodies against previously
described antigens at the node of Ranvier; CNTN1,10 neu-
rofascin 140 (NF140),24 neurofascin 155 (NF155),25 neu-
rofascin 186 (NF186),24 contactin-associated protein 2
(CASPR-2)26, and the CNTN1/contactin-associated pro-
tein 1 (CASPR1) complex10; and against other neural cell
adhesion molecules (L1CAM and NCAM1). Sera were
additionally screened for novel IgM and IgG reactivities
against primary cultures of rat peripheral nerve compo-
nents: dorsal root ganglia (DRG) neurons, motor neu-
rons, and Schwann cells.
Patients with autoantibodies against any of these nerve
structures were used for antigen discovery with immuno-
precipitation (IP) studies. If any candidate antigen was
detected, confirmatory experiments with transfected
human embryonic kidney (HEK) 293 cells were con-
ducted.
Autoantibody screening in peripheral nerve
components: cell cultures
Rat DRG neurons,27 motor neurons,28 and Schwann
cells29 were isolated and cultured as previously described
with modifications. Briefly, DRG neurons were dissoci-
ated from E16 embryos and cells were cultured in neu-
robasal medium (Gibco BRL, NY) supplemented with
B27 (Gibco BRL), Glutamax (Gibco BRL), and nerve
growth factor (NGF) (Invitrogen, CA). After 24 h, cyto-
sine arabinoside (ARA-C) (Sigma, MO) and fluorouracil
(5-FU) (both by Sigma) were added to the medium to
remove fibroblasts. Two-thirds of the ARA-C/5-FU-sup-
plemented medium was replaced with fresh medium every
other day until reaching DRG neuron full growth.
Motor neurons were obtained from spinal cords from
E16 rat embryos. Cells were cultured in neurobasal
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medium (Gibco BRL) supplemented with B27 (Gibco
BRL), Glutamax (Gibco BRL), and NGF (Invitrogen).
Medium was replaced every other day until full cell
growth was achieved.
Schwann cells were harvested from sciatic nerves from
4- to 6-day-old rat pups and cultured in CB-medium
overnight (O/N). After 24 h, medium was changed and
fresh CB-medium supplemented with ARA-C (Sigma)
was added. After 3 days, medium was changed to Sch-
wann cell proliferation medium, which was replaced every
other day until full proliferation was achieved. Cells were
then plated in Poly-D-Lysine (Sigma) coated cover
glasses, fixed with 4% paraformaldehyde (PFA) (Affyme-
trix Inc, CA), blocked with 5% goat serum (Gibco BRL)
and frozen at -80°C until immunocytochemistry (ICC)
experiments were performed.
DRG neuron, motor neuron, and Schwann
cell immunocytochemistry
Live DRG and motor neurons were incubated with
patients’ sera diluted 1/150 (for IgG experiments) or 1/40
(for IgM experiments) in culture medium. Cells were
then fixed with 4% PFA (Affymetrix Inc) and incubated
with appropriate secondary antibodies (both from Invit-
rogen) 1/1500. Due to the limiting scarcity of rat motor
neurons extraction, only patients’ sera were tested in these
experiments.
ICC experiments on Schwann cells were performed on
previously fixed and blocked frozen cells, using patients’
sera diluted 1/100 (for IgG) or 1/40 (for IgM) and 1/1000
secondary antibodies (both from Invitrogen).
Coverslips were mounted with Vectashield with DAPI
(Vector Laboratories, CA, USA) and fluorescence signal
intensity was scored in a 0–3 scale by two independent
researchers. Participants were codified as patients or con-
trols and their ICC results in each condition were grouped
in two separate categories: moderate to strong staining,
including scores two and three (relevant staining), and
other staining, featuring scores zero (negatives) and mild
(score one, unspecific background). The latter category
included sera with no immunological relevance. Images
were obtained with an Olympus BX51 Fluorescence Micro-
scope (Olympus Corporation, Tokyo, Japan) and processed
with GraphPad layout editor (GraphPad Software, CA).
Immunoprecipitation
Sera showing moderate or strong (scores 2 or 3) reactivity
against peripheral nerve cells were used for IP experi-
ments using the same cell as IP substrate. Briefly, cells
were cultured as described above and incubated 1 h at
37°C with sera diluted 1/100 (for IgG) or 1/40 (for IgM)
in growth medium. Cells were then lysed and protein A
and G agarose beads (both by Invitrogen) or anti-human
IgM agarose beads (Sigma) were added to the lysate and
incubated O/N. Agarose beads were then spun down and
the supernatants removed. Precipitated proteins were
detached from the agarose beads resuspending the sample
in Laemli buffer (Bio-Rad, CA, USA) with 5% b-mercap-
toethanol (Merck, Germany), heated up to 100°C for
5 min. Supernatants were then collected, loaded in a
polyacrylamide gel for electrophoresis and stained with
Coomassie blue (Invitrogen). Bands appearing in the IP
material were analyzed by mass spectrometry (MS). Pro-
tein relevance as an autoantigen was ranked by a custom
software (Anaxomics Biotech, Spain) according to an
algorithm taking into account MS protein features (score,
number of identified peptides, sequence coverage) and
protein’s cellular and tissular location and function. Pro-
teins in the IP material were selected as candidate anti-
gens when they fulfilled any of these criteria: protein
score > 100, peptide sequence coverage >5%, or two or
more peptides identified with the absence of the same
criteria in the control sample.
HEK cell transfection and ICC
HEK 293 cells were cultured O/N at 37°C in serum-sup-
plemented Dulbecco’s modified Eagle medium (Lonza,
Switzerland) in culture dishes with poly-D-coated (Sigma)
coverslips. Mammalian expression vectors encoding
human CNTN1, CASPR1, CASPR2, NF140, NF155,
NF186, NCAM1, and L1CAM (additional information in
Table S1) in Opti-MEM (Gibco BRL) were transfected
with Lipofectamine 2000 (Invitrogen). Cells were then
fixed with 4% PFA (Affymetrix Inc) and blocked for 1 h
with either 5% goat serum (Gibco BRL) or 1/40 normal
rabbit serum (Jackson Immunoresearch, PA, USA) in
PBS. ICC experiments were performed as described in
Table S1. Coverslips were mounted as described above.
Clinical–immunological correlations
Medical records of patients were retrospectively reviewed
in order to detect any clinical association with the pres-
ence of antibody reactivity. Detailed clinical features
(including phenotype at onset, time to nadir, electrophys-
iological features, and response to therapy) were collected
in a coded database to detect clinical–immunological
associations.
Statistical analysis
Results were analyzed by GraphPad Prism v5.0 (GraphPad
Software). Statistical comparison was performed using
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contingency analysis with the application of a two-tailed
Fisher’s exact test, accepting an alpha-level <0.05 to deter-
mine significance. Whenever this analysis could not be
performed due to high number of zeros in the equation,
a nonapplicable (NA) status was given in place of a
P value.
Results
Thirty-four patients with a neuropathy fulfilling diagnos-
tic criteria of possible (n = 9; 26.5%) or definite (n = 25;
73.5%) PN were included in the study, 8 (23.5%) of them
were women, while 26 (76.5%) were males. Mean age was
62.9  10.6 years; 57.4  12.1 years for women and
64.7  9.6 years for men. According to the recommended
diagnostic criteria for PNS,3 9 (26.5%) patients with a
possible diagnosis featured a nonclassical neurological
syndrome with presence of a tumor and absence of
onconeural antibodies. Patients with a definite diagnosis
either had a classical syndrome with a tumor and a lack
of antibodies (n = 24; 70.6%) or suffered from a tumor
and nonclassical syndrome that improved after oncologic
therapy (n = 1; 2.9%). Overall, 10 (29.4%) patients pre-
sented with a tumor and a neuropathy involving both
sensory and motor symptoms while lacking any known
antigen, while the remaining 24 (70.6%) patients pre-
sented with a tumor and a classical sensory neuronopa-
thy. Among the latter, 7 (20.6%) patients were diagnosed
with small cell lung cancer (SCLC). The rest of the 27
(79.4%) patients, regardless of their type of symptom,
sensory alone or sensory-motor, suffered from a myriad
of other malignancies (Fig. S1). Clinical and demographic
data are gathered in Table S2.
Screening experiments
ICC experiments with primary cultures of rat DRG neu-
rons, motor neurons, and Schwann cells were used to
identify novel IgG and IgM reactivities against neural
components. Overall, 9 (26.5%) patients reacted moder-
ately or strongly against DRG, motor neurons, or Sch-
wann cells, whereas 5 (17.9%) healthy controls reacted
only moderately. Since motor neuron staining in all
patients was exclusively moderate and poorly significant
(only three patients reacted, two of them moderately),
and due to the limiting scarcity of rat motor neurons, no
controls were tested for reactivity against motor neurons.
Patients with moderate and strong staining and their clin-
ical features are summarized in Table 1. Further details
regarding the remaining patients can be found in
Table S3. When comparing moderate to strong staining
intensities between all patients and controls, no significant
statistical differences were appreciated in any of our
screening experiments (Fig. 2A; Table S4). Differences
were nonetheless observed when stratifying by disease
phenotype.
Patients with sensory-motor neuropathy
In IgM experiments, 12 (35.3%) out of the total of
patients reacted against rat Schwann cells; 5 (14.7%) of
them featured strong or moderate staining (Fig. 1A). Four
(11.8%) out of these five patients, belonged in the cohort
of patients with sensory-motor neuropathy (n = 10), rep-
resenting 40.0% of these patients. A higher proportion of
patients with sensory-motor neuropathy reacted against
Schwann cells in IgM experiments compared to healthy
controls (P = 0.0028) (Fig. 2; Table S4) and to patients
with pure sensory neuronopathy (P = 0.0190) (Fig. 3;
Table S5). Three (8.8%) of these patients presented with
a sensory-motor axonal polyneuropathy with prominent
vibratory and joint position sensation involvement. How-
ever, shared specific clinical features among them could
not be identified. The fourth patient presented with a
sensory-motor neuropathy with demyelinating features in
the EMG. Clinical features are detailed in Table 1. Sera
from two of these patients (with strong reactivity against
Schwann cells) and a normal control were used to iden-
tify target antigens using Schwann cells as the IP sub-
strate. Unfortunately, no relevant antigens were identified
in comparison to the control serum.
Four patients (11.8%) with sensory-motor neuropathy
featured IgG reactivity against DRG neurons, 2 (5.9%) of
them moderate, while 3 (8.8%) featured IgM reactivity,
only 1 (2.9%) of them with moderate staining. Just 1
(2.9%) patient with sensory-motor neuropathy featured
moderate IgG motor neurons’ staining. These results were
not significant when compared to healthy controls (Fig. 2;
Table S4) or patients with sensory neuronopathy (Fig. 3;
Table S5).
Patients with pure sensory neuronopathy
Eight patients (23.5%) with sensory neuronopathy, pre-
sented IgG reactivity against DRG neurons, 2 (5.9%) of
them of a moderate kind (Fig. 1B), while only 2 (5.9%)
showed mild IgM reactivity. Sera from these two patients
showing moderate IgG reactivity against DRG neurons
and a normal control were used to identify target antigens
using DRG neurons as the IP substrate. These experi-
ments did not provide any candidate antigens in compar-
ison to the control serum.
Only 1 (2.9%) patient reacting moderately by IgM
against Schwann cells and another patient equally reacting
against motor neurons were identified in this cohort. No
cross-reactivity was found between motor neurons and
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Table 1. Patients with moderate or strong staining ICCs.
Patient
number NEUROPATHY TUMOR
DRG
neurons
IgG
DRG
neurons
IgM
Schwann
cells IgG
Schwann
cells IgM
Motor
neurons
IgG
Motor
neurons
IgM Clinical features
3 Sensory-motor OVARIAN 2 1 0 1 0 0 Rapidly progressive (over 1 month),
predominantly distal, severe limb
weakness plus ataxia. Very severe
impairment of arthrokynetic and
vibration sensation. Areflexia.EMG:
Demyelinating features with severe
axonal impairment and acute
denervation
4 Sensory-motor LYMPHOMA 1 2 0 31 0 0 Itch and paresthesia in 3 months.
Gait unsteadiness and frequent
falls. Mild distal weakness, severe
vibration sensation impairment.
Sudden progression to severe
quadriparesis. Areflexia.EMG:
severe sensory-motor axonal
polyneuropathy
7 Sensory-motor BREAST 0 0 0 31 0 0 One week of weakness and distal
paresthesia. Proximal (4/5) and
distal (3/5) weakness. Severe
vibration and arthrokynetic
sensation impairment in all four
limbs. Areflexia.EMG: axonal
polyneuropathy. Seventeen cells
and high protein content in CSF
33 Sensory-motor COLON 0 0 0 2 0 0 Mild gait impairment 1 year before.
Progression in last weeks, with
pan-sensory impairment in four
limbs. EMG: sensory-motor axonal
polyneuropathy. Dramatic
improvement after tumor removal
34 Sensory-motor THYMOMA 3 1 0 2 2 0 Gait impairment, distal sensory
disturbances, and distal weakness.
EMG: demyelinating features,
classified as CIDP. Improvement
with steroids
19 Sensory NSCLC 21 0 1 0 0 0 Left hand paresthesia. Progression
to all limbs, left side of face and
trunk. Gait ataxia. Abolition of
vibratory sensation in all four limbs.
Arthrokinetic sensation impaired in
left hand and foot. No weakness.
Areflexia. First EMG, normal.
Second EMG severe sensory
neuronopathy
21 Sensory TONSIL 0 0 1 2 0 0 Ataxia, paresthesia, vibration
sensation impairment, and global
areflexia.
30 Sensory NSCLC 21 0 0 0 0 0 Distal painful paresthesia in hands
and feet. EMG: sensory axonal
polyneuropathy
31 Sensory PAROTID
GLAND
0 1 1 0 1 2 Radicular pain in legs. Paresthesia in
four limbs and trunk. Progression
over 3 weeks to inability to walk.
Severe impairment of joint position.
High protein content in CSF
NSCLC, non-small-cell lung cancer; EMG, electromyography; CSF, cerebrospinal fluid.
1Indicate sera used for antigen discovery with immunoprecipitation (IP) studies.
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DRG neurons or Schwann cells. Significant differences
were not observed in these patients when compared to
healthy controls (Fig. 2; Table S4) or patients with sen-
sory-motor neuropathy (Fig. 3; Table S5).
Reactivity against cell adhesion molecules
No sera reacting against CNTN1, NF155, NF140, NF186,
NCAM1, L1CAM, or the CNTN1/CASPR1 complex were
identified in our study. Only 1 (2.9%) patient reacted
against CASPR2 (Fig. S2). This patient had a thymoma
and presented with a sensory-motor rapidly progressing
chronic polyradiculoneuropathy with demyelinating fea-
tures in the EMG, fulfilling diagnostic criteria of CIDP.
This patient did not show any evidence of neuromyotonia
(frequently associated with anti-CASPR2 antibodies and
thymoma26) and also reacted against DRG neurons and
Schwann cells.
Discussion
Although our study describes a comprehensive autoanti-
body screening approach aimed at identifying clinically
relevant antigens in PN and provides evidence of the
immunopathological diversity in these patients, our
experiments failed to identify novel antigens in PN and
strong clinical-immunological associations could neither
be drawn from our study. Disease heterogeneity and
reduced number of patients might be accountable for
these results.
Patients with sensory-motor PN featured IgM antibod-
ies targeting Schwann cells more frequently than healthy
controls (40% vs. 0%, P = 0.0028). Two of these patients
with a lymphoma and a breast adenocarcinoma were used
for IP experiments. IgM autoantibodies are not systemati-
cally screened in most autoimmune diseases. However,
several relevant autoantibodies in nonparaneoplastic
inflammatory neuropathies are of the IgM isotype. This
includes anti-MAG antibodies associated to monoclonal
gammopathy of unknown significance and plasma cell
dyscrasias,30 anti-GM1 antibodies in multifocal motor
neuropathy31, and anti-disialosyl antibodies in CANO-
MAD syndrome.32 Four out of 10 patients with sensory-
motor neuropathy stained Schwann cells. All of them had
an aggressive onset, three of them with predominantly
axonal features in the EMG. However, clear clinical–im-
munological correlations could not be inferred from our
findings. Technical caveats limit the efficiency of IP
experiments with IgM antibodies and patients with sen-
sory-motor PN are extremely rare. However, this specific
association will deserve attention and dedicated antigen
search using different approaches in future studies.
Almost 30% of patients reacted moderately or strongly
against neural structures; DRG neurons, motor neurons,
or Schwann cells. This may imply that the immune
response in PN is heterogeneous and directed toward
diverse antigens. However these results might reflect the
heterogeneity of cancer types and neuropathies present in
our cohort. A high proportion of healthy controls
(17.9%) reacted moderately against the same structures,
precluding any further interpretation of these findings.
Our study did not identify patients harboring antibod-
ies against neural cell adhesion molecules other than the
previously described CASPR2. Although the role of neural
cell adhesion molecules has been widely described to con-
tribute to cancer pathogenesis17–23 and nonparaneoplastic
Figure 1. Positive reactivities in screening ICC experiments. Strong IgM staining in Schwann cells (A) and moderate IgG staining in DRG
neurons (B).
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autoimmune neuropathies,10,24,25 the results in our study
suggest that nerve damage in our cohort cannot be attrib-
uted to a humoral autoimmune attack targeting L1CAM
and NCAM1 or the nodal/paranodal CNTN1/CASPR1
complex, CNTN1, NF140, NF155, or NF186. However,
this lack of antibodies should be confirmed in further
studies involving other cohorts of PN. Anti-CASPR2 anti-
bodies associate with neuromyotonia, limbic encephalitis,
and Morvan syndrome in patients with or without thy-
moma.33 Our CASPR2-positive patient presented a sen-
sory-motor neuropathy with demyelinating features in the
EMG and no evidence of central nervous system involve-
ment or neuromyotonia. This patient also showed rele-
vant IgG staining in motor and DRG neurons
experiments and IgM staining in Schwann cells, probably
reflecting the promiscuous immune response associated
with the thymoma.
In PNS, 70–80% of cases of subacute sensory neu-
ronopathy associate with SCLC, most of them boasting
anti-Hu antibodies. However, small subsets of patients
may present with anti-amphyphisin or anti-CV2 antibod-
ies (with or without anti-Hu antibodies) or with no anti-
bodies at all.34 In our study, 24 (70.6%) patients with a
definite diagnosis of PNS presented with a classical sen-
sory neuronopathy with a tumor and a lack of onconeural
antibodies. As most paraneoplastic pure sensory neu-
ropathies (neuronopathies) result from damage to the
DRG,4 our hypothesis in such patients were focused on
depicting impaired IgG/IgM autoimmune reactivity
against DRG neurons as previously described.35,36 How-
ever, interestingly, statistical results showed no significant
differences in such cells between those patients and
healthy controls or patients with sensory-motor neuropa-
thy in any of the tested conditions. Two of our patients
with pure sensory neuronopathy and non-small-cell lung
cancer showed moderate IgG staining against DRG neu-
rons and were used for IP experiments. Unfortunately, no
target antigens were identified from those experiments.
Since the description of anti-Hu antibodies in 1985,35
and following the identification of other highly specific
onconeural antibodies in the serum of PNS patients,37–43
current hypotheses suggest an autoimmune origin in
PNS.1 According to the location of the antigen, two types
of antibodies have been described in these conditions:
antibodies targeting cell membrane antigens or antibodies
against intracellular antigens, being the latter defined as
onconeural.44 In our study, antibody screening ICC
experiments and IP experiments were conducted in non-
permeabilizing conditions. Consequently, our search for
novel antigens was exclusively catered toward the detec-
tion of cell surface molecules, which was further con-
firmed by the membrane-staining patterns observed in
our results. Although no surface antigens were identified
Figure 2. Statistical comparison between patients and controls.
Statistical analysis of DRG and Schwann cells ICC considering moderate
or strong staining in all patients (A); patients with sensory neuronopathy
(B) and patients with sensory-motor (S-M) neuropathy (C).
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in our IP experiments, a role for intracellular antigens
in our patients cannot be ruled out and further compre-
hensive studies involving intracellular antigen screening
techniques should be conducted to address that search.
Another limitation in our study is the lack of inclusion of
a control group with sera from patients with cancer but
without neurologic involvement. Such approach was not
taken into consideration in this study due to the explora-
tory nature of our work and to the general negativity of
our results when compared against healthy controls.
Figure 3. Statistical comparison between PN patients with sensory neuronopathy and patients with sensory-motor neuropathy. Statistical analysis
of DRG neurons, motor neurons, and Schwann cells ICC considering moderate or strong staining in patients with sensory neuronopathy and
patients with sensory-motor (S-M) neuropathy.
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The use of antigens of nonhuman origin might be con-
sidered as a limitation in our study. Nonetheless, the use of
both mammalian expression vectors encoding nodal pro-
teins and neuronal primary cultures of murine origin has
previously provided us with relevant results.10,25 Despite
major sequence homology, interspecies variability may be
relevant enough to hinder novel antigen identification.
Thus, exploring novel viable sources of obtaining differenti-
ated human neural cells would greatly benefit the search of
new antigens, as has been proven in nonparaneoplastic
autoimmune neuropathies.45,46 Another limitation in our
study includes the lack of identification of antigens of lipidic
or glucidic nature. Last, identification of relevant protein
antigens using these techniques relies on completeness and
accuracy of existing databases, which may be biased in terms
of describing novel candidates. We used a custom software
setting a priori criteria to overcome this bias, however no
novel antigens could be identified from our IP studies.
In summary, we provide experimental evidence of the
heterogeneous IgG and IgM reactivity profile in PN
patients. Immunopathological diversity and reduced num-
bers in our cohorts may have hindered identification of
novel antigens. However, a significant proportion of PN
patients in our study harbor antibodies targeting neural
structures, which may suggest that novel neoplasm-asso-
ciated antigens remain to be discovered.
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